Question-and-Answer Session
Operator
Thank you (Operator instructions).
Carl Pelzel
Hey, operator, why don't we open up for questions?
Operator
Our first question comes from Scott Henry with Roth Capital.
Scott Henry – Roth Capital
Thank you and good afternoon. I guess just starting with the clinical timeline expectations and you may have hit on a few of these but I want to make sure that I had this right. In terms of the PHN indication, are we still looking for a data around the middle of this year?
Carl Pelzel
No. On PHN, that trial as I mentioned is progressing and we are anticipating results in 2009 but haven't been more specific about that. Reason is we have the trials up and running in the U.S. We have sites up and running in Russia. Argentina is not yet on board and we'll probably be in a better position, Scott, to give you an accurate run rate maybe at the end of this year and beginning of next.
Scott Henry – Roth Capital
Can you comment at all on where patient enrollment is?
Carl Pelzel
We'll probably do that in December.
Scott Henry – Roth Capital
Okay. And then, I guess, the Breeze 1 and Breeze 2 trials, I assume we will get data in 2010, is that correct?
Carl Pelzel
Let me ask Mike Sweeney to take that one.
Mike Sweeney
I was hoping that ours is a prevalent condition with lots of potential patients. We are hopeful that we find some data on books to these before the end of 2009. Obviously that's depending to our recruitment but we're optimistic before the end of 2009.
Scott Henry – Roth Capital
Okay, so for the shorter term line I imagine it will be 2009, and then the longer term trial will be 2010, correct?
Mike Sweeney
I am actually hoping for both of them. Don't forget the shorter term – the longer term had a headstart on the shorter term one.
Scott Henry – Roth Capital
Okay.
Mike Sweeney
So I would expect the results for them to be available around about the same time towards the end of next year.
Scott Henry – Roth Capital
Okay so I can assume enrollment is moving along pretty good on this.
Mike Sweeney
We made a good solid start.
Scott Henry – Roth Capital
Okay, as well just while we are on the R&D programs. The DM-1992 if I have that right, the Parkinson's disease program. What is the clinical benefit of that? I know you talked about a smoother release curve but I was off the call for a minute, but did you comment on the clinical benefits?
- To read the full transcript on Seeking Alpha, click here »
